What other drug will save 1 out of 4 patients that are S2C
First off, the data is only from critical patients, not S2C. The severe arm likely had a higher mortality rate in the leronlimab arm. The severe portion of the trial was 331 patients vs 62 critical so the severe data is far more reliable. Why was there no efficacy with severe patients? It makes no sense if leronlimab works.
It also doesn't heal 1 out of 4 with critical patients. That is the relative benefit, not the absolute benefit. Critical patients in the leronlimab arm had a 38% mortality. Critical patients in the placebo arm had a 47% mortality rate. 47% is 24% larger than 38% but it is an absolute benefit of 9%. Please stop repeating the lie that it saves 1 out of 4.
There were 62 critical patients. If 2 more placebo patients had survived, the placebo arm would have had a lower mortality percentage than the leronlimab arm. In other words, the mortality benefit is likely due to random luck.
News 
Market Data 
Discover 
